Posting of Annual Report and Notice of AGM

Summary by AI ^BETAClose X

Nuformix plc has announced the posting of its Annual Financial Report for the year ended 30 September 2025 and the Notice of the 2026 Annual General Meeting to shareholders. The company, which focuses on drug repurposing for fibrosis and oncology, has made the full PDF versions of these documents available on its website. The Annual General Meeting is scheduled to take place on 3 March 2026 at 9:30 a.m. at Arch Law, level 2, Huckletree, 8 Bishopsgate, London, EC2N 4BQ.

Disclaimer*

Nuformix PLC

05 February 2026

5 February 2026

Nuformix plc

("Nuformix" or the "Company")

Posting of Annual Report and Notice of Annual General Meeting ("AGM")

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the year ended 30 September 2025 (the "Annual Financial Report 2025") and the 2026 Notice of AGM are today being posted to its shareholders.

A full pdf version of the Annual Financial Report 2025 together with the Notice of AGM is available for download from the Investor Information section on the Company's website: www.nuformix.com.

The Annual General Meeting will be held at the offices of Arch Law, level 2, Huckletree, 8 Bishopsgate, London, EC2N 4BQ at 9.30 a.m. on 3 March 2026.

Enquiries:

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
CMC Markets
Douglas Crippen	+44 (0) 20 3003 8632

IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6632 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END